A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

BACKGROUND: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV monoclonal antibody (MAb). In preclinical in vitro and in vivo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Fernández, Pilar, Trenholme, Adrian, Abarca, Katia, Griffin, M Pamela, Hultquist, Micki, Harris, Brian, Losonsky, Genevieve A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2010
Gaiak:
Research article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2898783/
https://ncbi.nlm.nih.gov/pubmed/20525274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2431-10-38
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak